These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8334840)

  • 1. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
    Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
    Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
    [No Abstract]   [Full Text] [Related]  

  • 2. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
    Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
    Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
    Baba M; Kimura K; Suda T; Yagihashi S;
    J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
    [No Abstract]   [Full Text] [Related]  

  • 7. [Epalrestat].
    Hotta N
    Nihon Rinsho; 1997 Nov; 55 Suppl():204-11. PubMed ID: 9434468
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
    J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
    Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
    Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
    Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
    Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT).
    Matsuoka K; Sakamoto N; Akanuma Y; Hotta N; Shichiri M; Toyota T; Oka Y; Kawamori R; Shigeta Y;
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S263-8. PubMed ID: 17599629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
    Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
    Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
    Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
    Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
    Judzewitsch RG; Jaspan JB; Polonsky KS; Weinberg CR; Halter JB; Halar E; Pfeifer MA; Vukadinovic C; Bernstein L; Schneider M; Liang KY; Gabbay KH; Rubenstein AH; Porte D
    N Engl J Med; 1983 Jan; 308(3):119-25. PubMed ID: 6401351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial.
    Arezzo JC; Rosenstock J; Lamoreaux L; Pauer L
    BMC Neurol; 2008 Sep; 8():33. PubMed ID: 18796160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.